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Abstract
Background:  To assess the feasibility and efficacy of using 125I seed implantation under
intraoperative ultrasound guidance for unresectable pancreatic carcinoma.
Methods:  Fourteen patients with pancreatic carcinoma that underwent laparotomy and
considered unresectable were included in this study. Nine patients were pathologically diagnosed
with Stage II disease, five patients with Stage III disease. Fourteen patients were treated with 125I
seed implantation guided by intraoperative ultrasound and received D90 of 125I seeds ranging from
60 to 140 Gy with a median of 120 Gy. Five patients received an additional 35–50 Gy from external
beam radiotherapy after seed implantation and six patients received 2–6 cycles of chemotherapy.
Results: 87.5% (7/8) of patients received partial to complete pain relief. The response rate of
tumor was 78.6%, One-, two-and three-year survival rates were 33.9% and 16.9%, 7.8%, with local
control of disease achieved in 78.6% (11/14), and the median survival was 10 months (95% CI: 7.7–
12.3).
Conclusion: There were no deaths related to 125I seed implant. In this preliminary investigation,
125I seed implant provided excellent palliation of pain relief, local control and prolong the survival
of patients with stage II and III disease to some extent.
Introduction
The incidence of pancreatic carcinoma has increased in
recent decades, yet the treatment outcome for this disease
remains unsatisfactory. Despite the introduction of new
therapeutic techniques combined with aggressive modali-
ties, such as external beam radiotherapy (EBRT) and
chemotherapy, the prognosis of pancreatic carcinoma
remained to be very poor, with a mortality rate of more
than 90% [1]. Only 15% to 20% of patients with pancre-
atic carcinoma are suitable for resection, and even with
resection, long term survival still remains poor [2,3]. Most
of pancreatic carcinoma was diagnosed in the locally
advanced or metastatic stage, and the median survival rate
was approximately 6 months with palliative treatment.
Biliary and gastric bypass have been used for palliation in
unresectable pancreatic carcinomas and median survival
in these patients was often 5–6 months [4,5].
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More recently, EBRT and chemotherapy have been stand-
ard adjuvants for locally advanced pancreatic carcinoma.
EBRT alone has failed to control disease progression and
yields a median survival of 5.5–7 months [6,7], while the
addition of chemotherapy to EBRT increased the median
survival to 9–10 months [8-10]. The introduction of intra-
operative electron beam radiotherapy, combined with
EBRT and chemotherapy, has also failed to significantly
improve long-term results, with recent studies reporting
median survival rates of 7–16 months [11-14].
Despite the availability of many treatments, there was cur-
rently no consensus regarding the optimal therapeutic
modality for unresectable pancreatic carcinomas. There-
fore, it is necessary to investigate new techniques that may
improve the prognosis. In this study we investigated the
efficacy and feasibility of 125I seed implantation guided by
intraoperative ultrasound in managing unresectable pan-
creatic carcinoma.
Methods
Patient information and selection
Between October 2003 and February 2006, 14 patients
with a Karrnofsky performance status (KPS) score of 70 or
above (which is associated with a survival of >3 months)
were identified. Of these 14 patients, 50% (7/14) demon-
strated jaundice, 57% (8/14) suffered from pain, 21% (3/
14) suffered from intestinal obstruction and 93% (13/14)
experienced weight loss. These patients were evaluated as
unresectable pancreatic carcinoma by surgeons during
laparotomy and received 125I seed implantation guided by
intraoperative ultrasound. The criteria of unresectable dis-
eases included vascular invasion or vascular invasive com-
bined with metastasis to the local region lymph nodes. Of
the 14 pancreatic carcinoma patients, 9 were diagnosed
with stage II disease, 5 patients with stage III disease. A
summary of patient characteristics is listed in Table 1,
Table 2 and Additional file 1. Two of the patients with
jaundice did receive a biliary stent treatment one month
before 125I seed implantation. All patients were evaluated
for the extent of disease progression by physical examina-
tion, complete blood panel, chest X-ray, abdominal CT
scans and ultrasound before seed implantation. This study
was approved by the institutional review board and
informed consent was obtained.
Treatment planning
Patients underwent a detailed tumor volume study using
CT scans 1–2 weeks before seed implantation. Images of
each pancreatic carcinoma were obtained at 5 mm inter-
vals. The radiation oncologist and surgeons together out-
lined the gross tumor volume (GTV) on each image and
planning target volume (PTV) included GTV plus 0.5 – 1.0
cm peripheral tissue. These tracings were digitized and
scanned to define the tumor volume, from which the D90
of 60–140 Gy for 125I seed irradiation, with the median of
120 Gy and the number of 125I seeds to be implanted
could be calculated. The D90 was prescribed in a way that
at least 90% of the tumor volume received the reference
dose. The 125I seeds used (Beijing Atom and High Tech-
nique Industries Inc, Beijing, Modle-6711) had a half-life
t1/2 of 59.4 days with a low energy level of 27.4 KeV and a
half-value of 0.025 mm in lead. The computer treatment
planning system (Beijing Fei Tian Technique Industries
Inc, Beijing, China) was used for dose calculations.
Treatment technique
After the diagnosis of pancreatic cancer had been estab-
lished by biopsy intraoperation, tumor volume was meas-
ured during laparotomy by intraoperative
ultrasonography utilizing a megahertz linear probe.
Guided by ultrasound, 18-gauge needles were implanted
into mass and spaced in a parallel array at intervals of 1.0
cm, extending at least 0.5~1 cm beyond the margins of the
pancreatic lesions. During the placement of the needles,
care was taken to avoid the needles from the pancreatic
duct, small blood vessels, and the adjacent transverse
colon at least 1 cm. After needles were implanted, 125I
seeds were implanted using a Mick-applicator and the
spacing was maintained at 1.0 cm intervals (Figure 1). The
number of 125I seeds implanted ranged from 10 to 75,
with the median number implanted of 38. The specific
activity of 125I ranged from 0.40 to 0.60 mCi per seed, and
the total isotope radioactivity implanted ranged from 4 to
37.5 mCi. An omental fat pad was placed over the
implanted volume to protect the gastric and transverse
colon mucosa from irradiation. Postimplant EBRT was
generally recommended to all patients for an adjuvant
Table 1: Summary of patient characteristics (n = 14)
No of patients %
Gender
Male 7 50
Female 7 50
Stage II 9 64
pT3N0M0 6
pT1N1M0 0
pT2N1M0 0
pT3N1M0 3
Stage III 5 36
pT4N any Mo 5
Primary tumor location
Head 6 44
Body and/or tail 3 21
Head and body/tail 3 21
Whole pancreas 2 14
Symptoms
Jaundice 7 50
Pain 8 57
Weight loss 13 93
Intestinal obstruction 3 21
Pathology
Adenocarcinoma 14 100Journal of Experimental & Clinical Cancer Research 2009, 28:88 http://www.jeccr.com/content/28/1/88
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aim, but only 5 patients received EBRT at 4–6 weeks after
125I seed implantation. The total doses of EBRT ranged
from 35 to 50 Gy at 1.8–2.0 Gy per fraction. Postoperative
chemotherapy was recommended to all patients on an
adjuvant or palliative basis, but only six patients received
chemotherapy consisted of Gemcitabine or Paclitaxel
(PTX) and was completed 2 to 6 cycles. The other patients
refused to receive EBRT or chemotherapy furthermore
after seed implantation.
Definition for the clinical benefit response
The pain intensity was evaluated and graded by the Inter-
national Association for the Study of Pain [15]. Numerical
Rating Scale (NRS) 1–3 of pain was mild, NRS 4–6 was
moderate and NRS 7–10 was severe. The complete
response (CR) was no pain after seed implant, partial
response (PR) was pain relief, pain-free sleep and mainte-
nance of a normal life. No response (NR) was meaning no
change of pain severity compared with pre-seed implant.
The response rates (RR) of pain relief were defined as
moderate and severe pain decreasing to mild pain; the RR
was CR + PR. Tumor responses and toxicity were assessed
using WHO criteria [16]. In brief, a complete response
(CR) was defined as the complete disappearance of all
measurable lesions, without the appearance of any new
lesion. A partial response (PR) was defined as a reduction
in bidimensionally measurable lesions by at least 50 per-
cent of the sum of the products of their largest perpendic-
ular diameters and an absence of progression in other
lesions, without the appearance of any new lesion. Stable
disease (SD) was defined as a reduction in tumor volume
of less than 50 percent or an increase in the volume of one
or more measureable lesions of less than 25 percent, with-
out the appearance of any new lesion. Progressive disease
(PD) was defined as an increase in the size of at least 25%
percent and the appearance of any new lesions. The
response rate was CR + PR.
Follow-up and statistical analyses
One month after seed implantation, patients were evalu-
ated by radiation oncologists and surgeons by physical
examination, complete blood panel, chest X-ray, abdom-
inal CT and ultrasound. One month later, a clinical con-
sultation was provided. After that, evaluation was given
every 2–3 months or sooner if a new clinical sign or symp-
tom appeared. Time of survival was calculated from the
date of diagnosis to the date of death or last follow-up. A
Table 2: Characteristics of patients and treatment (14)
No Gender Age TNM Stage KPS Jaundice Surgery Other treatment Adjunant EBRT Adjunant CTx
(cycles)
1 F 64 pT3N0M0 II 80 Yes biliary enteric anastomosis 
+gastrojejunostomy
No 35 Gy/17 f  PTX(2)
2 M 53 pT3N0M0 II 80 Yes No PTCD+stent No No
3 F 71 pT3N0M0 II 80 No No PTCD+stent No No
4 F 66 pT3N1M0 II 80 No No No No No
5 M 65 pT3N0M0 II 80 Yes biliary enteric anastomosis No No No
6 M 75 pT3N0M0 II 70 Yes biliary enteric anastomosis 
+gastrojejunostomy
No No No
7 F 48 pT4N0M0 III 80 Yes biliary enteric anastomosis 
+gastrojejunostomy
No 40 Gy/20 f PTX(2)
GEM(2)
8 M 62 pT3N1M0 II 70 Yes biliary enteric anastomosis No No No
9 F 38 pT3N1M0 II 70 Yes biliary enteric anastomosis PTCD+stent No No
10 M 46 pT4N0M0 III 70 No No No 40 Gy/20 f GEM(4)
11 F 56 pT4N0M0 III 80 No No No No GEM(3)
12 M 41 pT4N0M0 III 80 No No No No No
13 F 43 pT3N0M0 II 90 No No No 50 Gy/25 f GEM(6)
14 M 52 pT4N1M0 III 80 No No No 50 Gy/25 f No
Abbreviations: KPS: Karnofsky; EBRT: external beam radiotherapy; CTx: chemotherapy; PTBD: percutaneous transhepatic biliary drainage; PTX: 
paclitaxel; Gem: gemcitabine.
Intraoperative ultrasound scan showing the distribution of  implanted seeds in the tumor Figure 1
Intraoperative ultrasound scan showing the distribu-
tion of implanted seeds in the tumor.Journal of Experimental & Clinical Cancer Research 2009, 28:88 http://www.jeccr.com/content/28/1/88
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local recurrence was defined as tumor progression (PD)
within the implanted area or surrounding regions as seen
on CT. Local recurrence and distant metastasis were
scored until patient death and censored thereafter. Overall
survival curves were generated using the Kaplan-Meier
method using SPSS10.0 and deaths for any reason were
scored as events.
Results
Relief of pain symptoms
Pain was the presenting symptom in 57.1% (8/14) of
patients prior to treatment. Following 125I seed implanta-
tion, the RR was 87.5% (7/8), two of patients with severe
pain become no pain, two of patients with severe pain
become mild pain, one of patients with severe pain
became moderate, two of patients with moderate pain
became no pain and one of patients with moderate
became mild pain. Most patients experienced pain relief
within one week following seed implantation.
Local control and survival
The response rate of tumor was 78.6%, overall local con-
trol rates in this study were 78.6% (11/14) (Figure 2) too.
The overall median survival was 10 months (95% CI, 7.6–
12.3), while the overall 1-, 2- and 3-year survival rates
were 33.9%, 16.9% and 7.8%, respectively. The Kaplan-
Meier actuarial survival curve of all 14 patients treated
with seed implantation is shown in Figure 3. Seven
patients died of metastases to the liver and peritoneal sur-
face, yet had no image evidence of any residual local dis-
ease. Two patients died of local progression, two patients
died of local progression and metastases, one patient died
of heart disease.
Toxicity and complications
No patient died during the perioperative period, although
chylous fistula was observed in one patient (7%). One
patient (7%) who underwent both seed implantation and
EBRT developed a gastric ulcer. One patient (7%) experi-
enced radiation enteritis and 7 (50%) patients experi-
enced fever. Clinical evaluation, ultrasound, and CT scans
determined that the majority of patients developed metas-
tases to the liver and peritoneal surface. Additionally, for
2 (14%) patients, three seeds were found to have migrated
to the liver in each case. However, no side effects were
observed for 12-months post-treatment.
Discussion
The treatment of unresectable pancreatic cancer continues
to be a major challenge. More than half of patients have a
locally or regionally confined tumor requiring local treat-
ment. Stereotactic radiotherapy (SRT) allows an escala-
tion of radiation doses to be applied to a small target
volume within a small margin. SRT is administered in one
or a few fractions with the goal of sparing the surrounding
normal tissue by using multiple non-coplanar field
arrangements for the administration. In a phase II study
on the use of SRT in the treatment of locally advanced
pancreatic carcinoma by Huyer et al, the median survival
time was only 5.7 months, and the one-year survival rate
was 5% [17]. These data associate SRT with a poor out-
come, unacceptable toxicity, and questionable palliative
effects, making SRT unadvisable for patients with
advanced pancreatic carcinoma. In contrast, interstitial
permanent implantation of radioactive seeds into the
Actuarial local control curve for 14 patients treated with 125 I  seed implantation Figure 2
Actuarial local control curve for 14 patients treated 
with 125 I seed implantation.
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Actuarial survival curve for 14 patients with unresected stage  II/III pancreatic carcinoma treated with 125I seed implantation Figure 3
Actuarial survival curve for 14 patients with unre-
sected stage II/III pancreatic carcinoma treated with 
125I seed implantation.
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tumor site provides the advantage of delivering a high
dose of irradiation to the tumor (range 140–160 Gy)
which drops off sharply outside the local implanted field.
125I seeds with a half-life of approximately 59.4 days were
selected as the radioactive source for permanent implan-
tation in this study, allowing approximately 95% of the
needed dose to be delivered within a year [18].
Implantation of radioactive isotopes for the treatment of
pancreatic carcinoma has been used for the past several
decades. For example, Handly et al. reported the use of
radium needle implantation in 7 patients for the treat-
ment of pancreatic carcinoma in 1934 [19]. Of those, one
patient survived up to two years. Hilaris, who was a pio-
neer in the development of 125I seeds for implantation for
the treatment of pancreatic carcinoma, published a study
of 98 patients receiving seed implants that responded
with a median survival of 7 months [20], with 1 patient
surviving for five years. Pain control was achieved in 65%
of patients and lasted between 5 and 47 months (with a
median of 6 months).
In a review study by Morrow et al., no difference in sur-
vival between patients treated with interstitial brachyther-
apy and patients treated by surgical resection at the same
institution were observed [21]. The median survival time
was 7 months, and at least one patient survived up to five
years. Pain control was achieved in 65% of the patients
[22]. Syed et al. reported 18 patients treated with biliary
bypass surgery, 125I interstitial brachytherapy, and EBRT
[23]. Ten patients with the interstitial brachytherapy were
"sandwiched" between two courses of EBRT. Typically,
patients received 30 Gy EBRT following biopsy and bypass
surgery, then 2 weeks later an additional interstitial brach-
ytherapy of 100–150 Gy, and then an additional 15–20
Gy EBRT was administered 3–4 weeks after interstitial
implantation. The results showed a 13 month median sur-
vival time in 12 patients with head and body pancreatic
carcinoma. 125I seed implantation has been attempted in
patients with locally advanced pancreatic carcinoma, and
no difference in overall survival was found compared with
the use of other techniques [24,25].
In this study, the interstitial needle position and distribu-
tion were determined using ultrasound supervision and
with the intent to spare at least 1 cm from nearby or nor-
mal tissues including the internal pancreatic duct and
small blood vessels. The placement of an omental fat pad
over the implanted volume was also used to protect the
gastric and transverse colon mucosa from irradiation. Our
results indicate that the local control of disease was
achieved in 78.6% of all patients. 87.5% (7/8) of all
patients experienced complete and partial pain relief and
shown satisfactory palliative effect. The overall 1-, 2- and
3-year survival rates were 33.9%, 16.9% and 7.8%, respec-
tively with the median survival of 10 months. The survival
rate and survival times were found to be the most advan-
tageous for some selected stage II/III patients in this study.
Permanent interstitial administration of radioactive seeds
appears to offer consistent and improved local control,
although a major drawback is the high rate of periopera-
tive morbidity and mortality. The significant causes of
high morbidity of 125I seed intraoperative implantation
were due to the needles penetrated into pancreatic duct,
small blood vessels in the pancreas and/or organ at risk
resulting in fistula and abscess formation. The major long-
term complication from the combined effects of multimo-
dality treatments has been gastrointestinal bleeding and
obstruction [26]. The high incidence of complications
maybe related to that the seeds were implanted nearby
normal tissues such as gastric, colon and jejunum. The
second reason may be the activity of seeds was high. The
third reason maybe the doses of seeds beyond the toler-
ance of normal pancreas tissue. In earlier studies, periop-
erative mortality was 16% – 25% from acute pancreatitis,
fistulization, and abscess formation [23]. Side effects
reported in the Hilaris et al., study included 1 patient
developing a post-operative mortality, another patient
suffered from a pancreatic fistula, 4 patients developed
biliary fistula, 4 developed abscesses, 4 developed gas-
trointestinal bleeding, 6 developed obstruction of the gas-
trointestinal tract, 5 patients developed sepsis, and 4
patients developed deep venous thrombophlebitis [20].
In comparison, the study by Syed et al. included 8 patients
with a poorer prognosis, 2 patients with prolonged
wound drainage, 3 patients developed insulin-dependent
diabetes, and 2 patients developed other interstitial com-
plications [23]. For this study, perioperative mortality was
considerably less than that observed in earlier studies, one
patient suffered from chylous fistula, one patient suffered
from pancreatitis and one suffered from gastritis, seven
patients suffered from low fever, there were no grade III
and grade IV toxicity and complications, and less than
most series of surgically-treated pancreatic cancer patients
published in the literature [22,27].
In conclusion, 125I seed implantation with intraoperative
ultrasound guidance provides a satisfactory distribution
of seeds in tumor mass, minimizes radiation to surround-
ing organs due to the sharp dose fall-off outside the
implanted volume, and generates no damage. We hypoth-
esize that a further improvement in median survival of
patients with unresectable pancreatic carcinoma may be
obtained with the combined aggressive use of EBRT, sys-
temic chemotherapy.
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